Dupixent

News

Look out Dupixent, Lilly's lebrikizumab is on the march

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner.

News

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi

News

Sanofi eyes 2022 filing for haemophilia drug fitusiran, desp...

Sanofi's much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 despite a problem with blood clots in some patients in late-stage testing.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Scotland opens door to Translarna for Duchenne muscular dyst...

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics' Translarna for the first time.

News

Lilly’s Olumiant is first JAK drug backed by NICE for eczema

Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known a

News

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for n...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala i

Look out Dupixent, Lilly's lebrikizumab is on the march

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Sanofi eyes 2022 filing for haemophilia drug fitusiran, desp...

Scotland opens door to Translarna for Duchenne muscular dyst...

Lilly’s Olumiant is first JAK drug backed by NICE for eczema

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for n...

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

Dupixent

Editor's Picks